This trend isn't about caring for people who are already old (that's the Aging Population trend) — it's a far more audacious bet: slowing, stopping, or reversing aging at the cellular level. Billionaires like Bezos and Altman are pouring in billions, Nobel-winning scientists have joined the field — but here's the honest catch up front: most of the work hasn't been proven in humans yet. This lesson is the map that strings the 7 categories together — which ones are dream science, and which are businesses already making real money today (each category has its own deep-dive chapter).
Novo Nordisk Targets Over $23 Billion in Pipeline Sales by 2035 as GLP-1 Competition Bites
Novo Nordisk is diversifying beyond its GLP-1 obesity and diabetes franchise, aiming to launch more than five potential blockbuster drugs by 2030 and generate over $23 billion in pipeline-related sales by 2035. The company, whose Ozempic and Wegovy have driven recent growth, has begun exploring the hair-loss market, which its Chief Scientific Officer says can leverage Novo's scientific knowledge, and plans to advance multiple Phase 3 programs across obesity, diabetes and other therapeutic areas. Chief Executive Mike Doustdar acknowledged the loss of confidence, saying it takes time and hard work to build back, after the company's post-Wegovy strategy presentation sent hair-loss drug developers Veradermics and Absci higher. Novo has lost ground to rival Lilly in the injectable GLP-1 market and faces key semaglutide patent expirations in major markets in the early 2030s, prompting Morgan Stanley to downgrade the stock to Sell on medium-term growth concerns. Novo trades at around 10.2x forward GAAP earnings, below its five-year average of 30.0x and the sector median of 23.3x, while its forward price-to-sales ratio of 3.8x is below its five-year average of 9.6x and broadly in line with the sector median of 3.7x.
Eli Lilly Reports New Efficacy Data for Foundayo, EloraTZP and Ebglyss at EASD
Eli Lilly and Company presented new efficacy data from studies of its marketed and investigational metabolic medicines at the annual European Association for the Study of Diabetes conference. In the phase III ACHIEVE-4 study, Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist approved for chronic weight management, demonstrated a non-inferior risk of major adverse cardiovascular events versus titrated insulin glargine, with MACE-4 risk 16% lower, MACE-3 risk 23% lower, cardiovascular death risk 53% lower and all-cause death risk 57% lower; at 52 weeks A1C declined 1.6% versus 1% and body weight fell 8.8% versus a 1.7% increase, while 10.6% discontinued due to adverse events. Lilly also reported positive 48-week results from a phase IIb study of EloraTZP, an investigational combination of eloralintide and Zepbound, in adults with obesity or overweight and type II diabetes, where the highest-dose combination of 9 mg eloralintide plus 15 mg Zepbound reduced body weight by 23.3% (54.1 pounds) versus 14.8% (34.4 pounds) for Zepbound 15 mg alone, and A1C declined 2.9% versus 2.4%. Separately, the phase IIIb ADtouch study of Ebglyss (lebrikizumab-lbkz) met its primary and secondary endpoints, with 53% of patients on monotherapy achieving clear or almost clear hands and feet at week 16 versus 27% with placebo, and Lilly has submitted the data to the FDA seeking a potential U.S. label expansion to include localized atopic dermatitis with moderate-to-severe hand and foot involvement. Lilly has also submitted a regulatory filing to the FDA seeking approval of Foundayo for the treatment of type II diabetes, with the application currently under review, intensifying its oral GLP-1 competition with Novo Nordisk's oral Wegovy, Ozempic and Rybelsus.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Competition
LLY · Technology · Positive Positive efficacy data for Foundayo, EloraTZP and Ebglyss, plus FDA submissions for label expansion and type II diabetes approval.
NVO · Competition · Negative Lilly's Foundayo type II diabetes filing intensifies oral GLP-1 competition with Novo Nordisk's oral Wegovy, Ozempic and Rybelsus.
NURA Bangkok Clinic Partners with Ruamjairak Hospital to Build a Comprehensive Referral Network
NURA Bangkok Clinic, or Fujifilm DKH (Thailand) Co., Ltd., has announced a partnership with Sukhumvit 62 Medical Co., Ltd., or Ruamjairak Hospital, through the signing of a memorandum of understanding, or MOU, appointing Ruamjairak Hospital as the first Care Partner Network of NURA Bangkok Clinic. The collaboration is part of the development of a Continuity of Care Ecosystem, linking everything from preventive health checkups and early-stage risk screening to further diagnosis, access to specialist doctors, and appropriate, continuous and timely treatment. NURA Bangkok Clinic focuses on health checkups and preventive screening for cancer and heart disease through screening programs for cancer and non-communicable chronic diseases, or NCDs, using an Ultra Low-Dose CT Scan together with Fujifilm's AI-powered analysis system, under the concept of a complete examination within 120 minutes, from the start of the scan to seeing a doctor, with clients not required to fast or abstain from water beforehand. Under this collaboration, if screening results at NURA Bangkok Clinic reveal a risk or abnormality requiring further examination, clients can be referred to Ruamjairak Hospital to proceed with further diagnosis, consultation with specialist doctors, and appropriate treatment. Sittivech Sawetphat, General Manager of Fujifilm DKH (Thailand) Co., Ltd., said the company aims to encourage Thais to recognize the importance of preventive health checkups and early-stage screening for cancer and cardiovascular disease risk. Meanwhile, Apirak Apisanthanarak, Managing Director of Ruamjairak Hospital, said the collaboration reflects a shared goal of building a patient-centered healthcare system.
NURA Bangkok Clinic · Demand · Positive NURA Bangkok Clinic partners with Ruamjairak Hospital to build a Continuity of Care referral network for its health checkup and screening clients.
Fujifilm DKSH (Thailand) Co., Ltd. · Demand · Positive NURA Bangkok Clinic (Fujifilm DKH Thailand) signs MOU making Ruamjairak Hospital its first Care Partner Network, expanding referrals for its screening services.
Ruamjairak Hospital · Demand · Positive Ruamjairak Hospital becomes the first Care Partner Network of NURA Bangkok Clinic, gaining a referral pipeline for further diagnosis and treatment.
Regeneron's Trevogrumab Preserves 70% of Muscle Loss in Phase 2 COURAGE Trial
Regeneron Pharmaceuticals announced new Phase 2 COURAGE trial results showing that trevogrumab prevented 70% of the muscle loss associated with semaglutide treatment in people living with obesity. In a predefined MRI substudy, lower-dose trevogrumab preserved almost 70% of the thigh muscle that would otherwise have been lost with semaglutide alone, with 71.8% preservation at 52 weeks for the 25 mg dose and 68.9% for the 75 mg dose relative to placebo plus semaglutide. The lower-dose portion of the trial, which evaluated trevogrumab at 25 mg or 75 mg in combination with semaglutide 2.4 mg over 52 weeks, replicated the higher-dose findings, preserving lean mass at both 26 and 52 weeks, the primary endpoint, though it did not meaningfully enhance weight loss achieved with semaglutide alone. A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide and more preservation with trevogrumab. The results were presented at the European Association for the Study of Diabetes Annual Meeting and are in press with The Lancet, and Regeneron is planning to initiate a Phase 2 trial of trevogrumab in combination with GLP-1 receptor agonist-based therapies in older adults with obesity and decreased muscle mass and/or strength.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Technology
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Technology
REGN · Technology · Positive Phase 2 COURAGE trial showed trevogrumab preserved ~70% of muscle loss from semaglutide, a positive R&D readout for Regeneron.
DenmarkUnited StatesUnited Arab EmiratesUnited KingdomGermany
GLP-1 Healthspan Proxies▲2
Novo's Oral Wegovy Shows 4.1% Weight Loss After Switching From Injections
Novo Nordisk's oral Wegovy, or semaglutide, produced real-world weight loss in adults with overweight or obesity who switched from injectable GLP-1 therapies, according to data from the OCTANE study presented at the European Association for the Study of Diabetes on Sept. 30, 2026. The retrospective analysis, which drew on de-identified data from the Ro telehealth platform, covered 194 participants who moved from injectable Wegovy or Eli Lilly's Zepbound, or tirzepatide, to once-daily oral Wegovy between Jan. 5 and Feb. 7, 2026, and stayed on the pill for three months with weight data available at baseline and follow-up. Participants lost an average of four kilograms, or 8.8 pounds, over three months, equal to 4.1% of baseline body weight, while 40.7% achieved at least 5% weight loss and the share with a BMI of at least 30 kg/m2 fell 21.6 percentage points, from 87.1% at baseline to 65.5% at three months. Among participants with available information, 82.4% reported at least one treatment improvement, most often better-fitting clothes and healthier eating. Novo cautioned that the observational design cannot establish causality and cited limitations including variable data collection, self-reported measures, selection bias from requiring treatment persistence and limited generalizability. The Wegovy pill has launched in the United States, the United Arab Emirates, the United Kingdom and Germany, with additional select markets planned in coming quarters. Separately at the same conference, Novo presented 52-week functional MRI data showing CagriSema, its investigational once-weekly combination of cagrilintide and semaglutide, altered brain responses to high-calorie food cues and was linked to a 22.4% body-weight reduction versus placebo, along with a 14.3% weight reduction at week 40 in a diabetes MRI sub-study of the phase IIIa REIMAGINE 1 trial and a 14.2% weight reduction at week 68 in a post hoc analysis of phase III REIMAGINE 2. Novo submitted a new drug application to the FDA for CagriSema in weight management in December 2025, with a decision expected in the fourth quarter, and in 2026 began a phase III study of high-dose CagriSema 2.4 mg/7.2 mg in adults with obesity.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Technology
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Technology
NVO · Technology · Positive OCTANE data show oral Wegovy produced 4.1% weight loss over three months in patients switching from injectables, supporting its oral GLP-1 product
Novo Nordisk Says Wegovy Cut Liver Fat to Normal in 9 of 10 Obese Adults
Novo Nordisk reported that Wegovy, its injectable semaglutide, brought liver fat down to normal levels in nearly nine out of ten adults with obesity and excess liver fat, according to a post hoc analysis of a 55-participant sub-population of the STEP UP trial presented at the European Association for the Study of Diabetes Annual Meeting 2026 in Milan. Among the 26 participants who entered with liver fat above 5%, 88.5%, or 23 people, reached the below-5% threshold by week 72, while mean liver fat across the group fell from 8.8% at baseline to 3.1% at week 72 as measured by magnetic resonance imaging. The analysis pooled 1,919 adults from the STEP UP and STEP UP T2D trials, of whom 1,312 received semaglutide 7.2 mg, 304 received semaglutide 2.4 mg and 303 received placebo, and more than 94% were classified as high risk for fatty liver by the Fatty Liver Index at baseline. Eric Lawitz of the Texas Liver Institute and University of Texas Health San Antonio said the findings suggest semaglutide may help address liver disease early, noting that as many as three in four people with obesity may have excess liver fat. Novo chief medical officer Filip Knop said the results help show the quality of weight loss seen with semaglutide, adding that the dedicated ESSENCE MASH trial demonstrated reversal of liver damage in people with MASH. Semaglutide 2.4 mg is approved for the treatment of MASH under the Wegovy brand in the United States, Canada, the United Kingdom, China and several other markets, while semaglutide 7.2 mg is not being investigated for MASH.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Demand
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Demand
NVO · Technology · Positive Post hoc STEP UP analysis showed Wegovy/semaglutide normalized liver fat in ~9 of 10 obese adults with excess liver fat, supporting its clinical benefit.
Novo's Ozempic Cuts Cardiovascular Risk More Than Lilly's Mounjaro in Real-World Study
Novo Nordisk said new real-world data from its COMPETE SWITCH Cardiovascular study found that type II diabetes patients who increased their Ozempic dose had a lower observed risk of major adverse cardiovascular events than those who switched to Eli Lilly's Mounjaro. In the study, 67.2% of patients remained on Ozempic 1 mg within 365 days, 29.2% increased their dose to 2 mg and 3.6% switched to Mounjaro; by 720 days, 57.4% remained on semaglutide 1 mg, 36.9% had escalated to 2 mg and 5.7% had switched to Mounjaro. After adjustment for between-group differences, patients who increased their dose to Ozempic 2 mg had a statistically significant 6% lower risk of MACE than those who switched to Mounjaro, including doses of up to 15 mg, with MACE defined as all-cause death, heart attack and stroke. Novo cautioned that the study showed an association, not proof, that Ozempic 2 mg directly reduces cardiovascular risk more than Mounjaro, and that safety outcomes were not evaluated. Year to date, Novo shares have lost 22.2% against the industry's 14.9% growth.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Competition
Aging Population › Chronic-Disease Pharma Franchises ▲Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Competition
NVO · Technology · Positive Novo's own COMPETE SWITCH study found escalating to Ozempic 2 mg was associated with a statistically significant 6% lower MACE risk than switching to Mounjaro.
LLY · Competition · Negative Real-world COMPETE SWITCH data show patients on Ozempic 2 mg had a 6% lower MACE risk than those who switched to Lilly's Mounjaro, a competitive blow to Mounjaro.
Eli Lilly's EloraTZP Combo Cuts 23.3% of Weight in Phase 2b Trial
Eli Lilly reported that its experimental obesity and type 2 diabetes combination EloraTZP delivered up to 23.3% average weight loss in a Phase 2b trial, sending its shares up as much as 2.6% before closing 0.5% higher. In the 48-week trial of 367 participants, the combination of eloralintide and tirzepatide produced average weight loss of up to 54.1 lbs, or 23.3%, far outpacing the 34.4 lbs, or 14.8%, achieved by a 15 mg dose of tirzepatide alone. EloraTZP also reduced A1C levels by an average of up to 2.9%, compared with 2.4% for tirzepatide, and met all primary and secondary endpoints across the tested dose combinations, with the highest dose of 9 mg eloralintide plus 15 mg tirzepatide yielding the greatest reductions. The triple-hormone therapy activates GIP, GLP-1 and amylin; gastrointestinal side effects were the most common, and discontinuation rates for EloraTZP ranged from 10.8% to 27.0%, versus 2.9% for tirzepatide alone and 16.7% for placebo. Following the results, presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan, Italy, Eli Lilly plans to begin Phase 3 trials of EloraTZP in the fourth quarter of 2026, while shares of rival Novo Nordisk slipped 0.3%.
Novo Nordisk's CagriSema Cuts 'Food Noise' and Body Weight 22.4% in EASD 2026 Data
Novo Nordisk presented new data at the European Association for the Study of Diabetes Annual Meeting 2026 showing that its investigational obesity and diabetes drug CagriSema changes brain responses to high-calorie food cues and reduces harmful fat around organs while maintaining bone health. In a 52-week functional magnetic resonance imaging study in adults with overweight or obesity, CagriSema improved eating behaviour and reduced 'food noise', cravings, hunger and appetite, and was associated with a 22.4% reduction in body weight versus placebo at 52 weeks. Separately, in a diabetes MRI sub-study of the phase 3a REIMAGINE 1 trial in adults with early type 2 diabetes, CagriSema 2.4 mg/2.4 mg produced significant reductions in fat in the abdomen and around the liver and pancreas alongside a 14.3% body-weight reduction at week 40, while a post hoc analysis of bone markers from the phase 3 REIMAGINE 2 trial showed signs of healthy bone maintenance alongside a 14.2% body-weight reduction at week 68. Novo Nordisk submitted a New Drug Application for CagriSema for weight management to the US Food and Drug Administration in December 2025, with a decision expected in Q4 2026, and initiated a phase 3 trial of high-dose CagriSema 2.4 mg/7.2 mg in adults with obesity in 2026.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Technology
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Technology
NVO · Technology · Positive New EASD 2026 data show CagriSema cuts 'food noise' and body weight 22.4%, supporting its investigational obesity/diabetes profile.
AIA Partners with VitalLife to Launch Health Services for High-Net-Worth Clients in January 2027
AIA Thailand has announced a major strategic partnership, called the Frontier Strategic Partnership, with VitalLife Wellness Center, an international wellness center under Bumrungrad Hospital, or BH, to develop a new approach to healthcare for high-net-worth clients. Ekrit Thitimun, Chief Insurance Business Officer of AIA Thailand, said the partnership will elevate the health experience to better meet consumers' needs on a more personalized basis. The services offered cover in-depth health assessments, hormone balance and nutritional analysis, genetic factor assessment, consultations to design personalized health care plans, as well as rehabilitation and wellness services. AIA's high-net-worth clients can access the services through the AIA Prestige Club program and connect seamlessly with Bumrungrad Hospital's network of specialist doctors. Assistant Professor Dr. Polkrit Teekhareekul, Chief Executive Officer of VitalLife Wellness Center and Esperance, said the partnership expands the scope of wellness from specialized services to an ecosystem of life. More than 100,000 clients in the AIA Prestige Club program will begin accessing this new health care service starting in January 2027.
AIA Thailand · Demand · Positive AIA Thailand launches Frontier Strategic Partnership giving its Prestige Club clients new personalized health services, enhancing its offering to high-net-worth customers.
BH.BK · Demand · Positive VitalLife, under Bumrungrad Hospital, partners with AIA to serve 100,000+ high-net-worth clients, expanding patient demand for its wellness and specialist network.
Hengrui Medicine signs overseas licensing deal for HRS-1596 with Novo Nordisk, with potential total value of up to 2.6 billion US dollars
Hengrui Medicine announced that it has signed a licensing agreement with Novo Nordisk for the HRS-1596 project, granting the global weight-loss drug leader Novo Nordisk rights to its independently developed HRS-1596. The potential total transaction value is up to 2.6 billion US dollars, marking another step forward for Chinese innovative drug companies in the global weight-loss sector. On the same day, Dizal Pharmaceutical announced that it recently received a 600 million US dollar upfront payment from AstraZeneca. Boosted by this news, on September 30, the medical services concept rose 3.22 percent intraday, Yiqiao Shenzhou rose 13.14 percent, Nanmo Bio rose 10.70 percent, Berry Genomics rose 10.02 percent, Biopsychus rose 8.02 percent, and PharmaBlock Sciences rose 5.61 percent. Industrial Securities believes that innovation plus globalization remains the main theme for the pharmaceutical sector throughout the year. Multinational pharmaceutical companies facing patent cliffs need external pipelines, while domestic drug companies' R&D efficiency advantages are becoming more prominent, and cooperation models are upgrading, representing an increase in China's innovative voice.
Zealand Pharma Publishes Phase 2 ZUPREME-1 Petrelintide Results in The Lancet Diabetes & Endocrinology
Zealand Pharma announced that results from its Phase 2 ZUPREME-1 trial of investigational petrelintide have been published in The Lancet Diabetes & Endocrinology, with additional data to be presented at EASD 2026 on September 30 at 3:30pm CEST. In the randomized, double-blind, placebo-controlled, dose-finding trial, 485 adults with a mean age of 47 years and a BMI of 36.7 kg/m² were assigned 5:1 to once-weekly subcutaneous petrelintide at 1.0 mg, 2.5 mg, 5.0 mg, 7.0 mg or 9.0 mg, or placebo, for 42 weeks including dose escalation. Petrelintide led to mean body weight reductions from baseline to week 42 of up to 10.7% versus 1.7% for placebo on the efficacy estimand, and up to 10.2% versus 1.4% on the treatment policy estimand. Gastrointestinal adverse events were generally mild and occurred at rates similar to placebo, with no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events at the maximally effective dose. Treatment was also associated with reductions in waist circumference of up to 10.8 cm versus 4.3 cm with placebo, up to 41% reductions in high-sensitivity C-reactive protein versus 6% with placebo, triglyceride reductions of up to 21% versus 9%, and a mean pulse rate reduction of up to 2.9 beats per minute versus a mean increase of 0.3 bpm with placebo. Petrelintide is being evaluated for chronic weight management in three global Phase 3 registrational trials, and a Phase 2 trial of petrelintide in combination with enicepatide is planned for initiation in the second half of 2026.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Technology
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Technology
0NZU.LSE · Technology · Positive Phase 2 ZUPREME-1 results for petrelintide published in The Lancet show up to 10.7% weight loss with clean GI safety, advancing its obesity pipeline.
Novo Nordisk Licenses Once-Weekly Oral GLP-1/GIP Drug From Hengrui Pharma
Novo Nordisk has entered an exclusive license with Hengrui Pharma for a once-weekly oral GLP-1/GIP dual agonist, adding a late-stage oral candidate to its metabolic pipeline. The deal complements Novo Nordisk's existing injectable and oral GLP-1 work and sits alongside its Nanexa long-acting injectable agreement and Orbis macrocycle partnership. Separately, Phase 3 CagriSema data delivered new weight management clinical results, with a CagriSema NDA decision expected in the fourth quarter of 2026. The CHMP issued a positive opinion backing Sogroya for idiopathic short stature and supported FREHEMGO for hemophilia A patients, with European Commission rulings on both still pending. Novo Nordisk, a pharmaceuticals group with a DKK1.1 trillion market cap, is also pursuing a MASLD and MASH collaboration with Siemens Healthineers.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Technology
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Technology
NVO · Demand · Positive Novo Nordisk gains a late-stage once-weekly oral GLP-1/GIP candidate, expanding its metabolic pipeline alongside existing GLP-1 work.
600276.CG · Demand · Positive Hengrui Pharma licenses its once-weekly oral GLP-1/GIP dual agonist to Novo Nordisk in an exclusive deal, validating its pipeline asset.
Eli Lilly Shares Rise After Foundayo Shows More Weight Loss
Eli Lilly shares edged 1% higher in morning trading Tuesday after new data showed its oral Foundayo treatment produced greater weight and blood-sugar reductions than oral semaglutide at higher doses. The analysis examined 17.2 mg of Foundayo, or orforglipron, in adults with type 2 diabetes, and at week 52 patients receiving the Lilly drug recorded 1.5% more body-weight reduction than those taking 25 mg of oral semaglutide. The blood-sugar measure A1C also moved in Lilly's favor, with the analysis showing a further 0.3% reduction compared with the semaglutide group. The findings were presented during the European Association for the Study of Diabetes meeting in Milan, where EASD materials listed additional studies involving the treatment. Lilly has been developing Foundayo across its diabetes program as competition in oral GLP-1 medicines expands, though the comparison comes from separate studies rather than a direct head-to-head trial.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Competition
Aging Population › Chronic-Disease Pharma Franchises ▲Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Competition
LLY · Technology · Positive New data showed Lilly's oral Foundayo produced greater weight and blood-sugar reductions than oral semaglutide at higher doses.
Lilly Says Higher-Dose Zepbound Widened Weight-Loss Lead Over Wegovy
Eli Lilly says higher doses of Zepbound may have widened its weight-loss advantage over Novo Nordisk's Wegovy. A new indirect analysis found that patients receiving Zepbound 15 mg and 10 mg had 4.5 percentage points and 3.2 percentage points more weight loss, respectively, over 72 weeks than patients taking high-dose Wegovy. According to Lilly, patients receiving Zepbound 15 mg were three times more likely to lose at least 20% of their body weight compared with those receiving Wegovy HD, and the difference was even more pronounced among people reaching larger weight-loss goals. Discontinuation rates because of adverse events were comparable across the Zepbound 10 mg, Zepbound 15 mg and Wegovy HD groups. Lilly cautioned that the results did not come from a direct head-to-head trial, comparing data from its Phase 3 SURMOUNT-1 study with Novo Nordisk's STEP UP studies. Novo shares were down about 1.3% in Tuesday premarket trading, while Lilly was up roughly 0.4%.
Longevica Forms Scientific Advisory Board to Advance Longevity Pipeline
Longevica Therapeutics announced the formation of its Scientific Advisory Board, marking the preclinical biotech's pivot from foundational discovery to clinical execution and drug development. The company invested four years and $13 million in what it calls the world's largest in vivo mammalian screening program at The Jackson Laboratory, tracking 1,033 small-molecule compounds across more than 16,000 subjects over their natural lifespans. From that screen, 60-plus compounds extended mammalian lifespan by over 10% to 22%, and the company is now pursuing two novel classes of health-and-lifespan therapeutics alongside targeted drug repurposing for cardiovascular, metabolic, fibrotic, and systemic disease. The advisory board spans scientific, clinical, strategy, and business roles, including Dr. Steven Garan of UC Berkeley as Chief Scientific and Technology Advisor, Dr. Mike Zack as Chief Medical and Scientific Advisor, and Allan Gobbs of ATEM Capital as Corporate Strategy and Finance Advisor. The move follows the recent appointment of former Genentech, Roche, and NCI/NIH leader Dr. Prasun Mishra as Chief Executive Officer.
Longevity & Life Extension › Metabolic Aging & Geroprotectors ▲Technology
Longevica Therapeutics · Technology · Positive Longevica formed a Scientific Advisory Board to advance its longevity drug pipeline from preclinical discovery to clinical execution, with 60-plus compounds extending mammalian lifespan.
Stock Exchange orders SPTX to clarify 1,195 million baht investment in Rasmipoom Beauty Anti-Aging
The Stock Exchange of Thailand has ordered SPTX, or SPTX, to clarify details of its 1,195 million baht investment in Rasmipoom Beauty Anti-Aging Co., Ltd., requiring the clarification to be submitted through the exchange's disclosure system by October 5, 2026, and the company's board and audit committee to give their opinions by October 12, 2026, while warning investors to study the information carefully before deciding to invest. On September 15, 2026, the SPTX board resolved to invest 1,195 million baht in the target company, representing a 92% shareholding, by purchasing shares from Rasmipoom Holding (Thailand) Co., Ltd. and Rasmipoom Holding (Hong Kong) Co., Ltd., both wholly owned by Mr. Rasmipoom Sumetheewit. The transaction qualifies as a significant acquisition of assets, with a maximum transaction size of 50.52% of total assets, and is a connected transaction, since Mr. Rasmipoom is a major shareholder and vice chairman of SPTX; after the transaction his SPTX stake will rise from 21% to 43%. As of June 30, 2026, the target company had assets of 306 million baht, shareholders' equity of 187 million baht, and net profit of 32 million baht for the six-month period. After the investment, the sellers will hold 8% of the target company and have the right to nominate at least 2 of 5 directors, with approval of major transactions requiring the consent of the seller group. The company will transfer the land and buildings that house two clinic branches and constitute its main assets back to the sellers and enter into a leaseback agreement to continue operating the business, and the sellers have agreed to a performance guarantee for five years after SPTX acquires the business, covering the expansion of no fewer than 9 branches. The exchange has asked SPTX to clarify five additional points: the timeline of Mr. Rasmipoom's shareholding and preparations for the investment; the rationale and necessity for transferring the land and buildings to the sellers and leasing them back, which will create significant related-party transactions in the future; information supporting the pricing criteria and key assumptions, including whether the land and buildings are included in the price; the proportion of SPTX's assets or operating revenue that will change and the reasonableness of the management authority and board structure at the target company; and the opinions of the board and audit committee on the reasonableness of control rights, the trading conditions, the adequacy of the investment funds, the results of the business due diligence, and the action plan if operating results or branch expansion do not meet the sellers' guarantees.
Longevity & Life Extension › Longevity Clinics & Healthspan Services Capital
SPT X Public Company Limited · Regulation · Neutral Stock Exchange of Thailand orders SPTX to clarify its 1,195 million baht connected-party acquisition of Rasmipoom Beauty Anti-Aging.
Rasmiphum Beauty Anti-Aging Co., Ltd. · Capital · Neutral SPTX agreed to acquire 92% of Rasmipoom Beauty Anti-Aging for 1,195 million baht, a related-party asset acquisition now under exchange scrutiny.
TRP Expands Hair Transplant Services and Longevity Market, Targeting International Clients
Aesthetic Connect Public Company Limited, or TRP, is pushing ahead with new services in hair transplantation and the longevity market, while stepping up aggressive marketing to capture international clients across both Europe and Asia. Chief Executive Officer Pornpiwan Niramoncherdchai said the company will maintain its existing strength in facial plastic surgery, which generates nearly all of its revenue, and build on it with specialised medical teams and well-equipped medical facilities. The hair transplant service is now available and is expected to offer customers more options and open the door to new target groups distinct from facial surgery clients. Meanwhile, the longevity market, which covers long-term health care, anti-aging and preventive care, represents another opportunity to extend the beauty business into services that better meet customer needs and to create a new revenue base in the future. On marketing strategy, the company will take a more aggressive approach to reach customers across a range of ages, lifestyles and service needs, tailoring its marketing to each area rather than applying the same strategy across all markets. The company also expects to stay on track with its financial targets under the strategy of its new CEO, which focuses on preserving the strength of the facial surgery business as the core business while generating new growth from new services and expanding its international customer base.
TRP.BK · Demand · Positive TRP is launching hair transplant and longevity services and aggressively marketing to international clients, expanding its service offerings and target customer base.
TMAN opens Heaven Herb factory, moves into Longevity market, targets 5-10% of revenue within 3-5 years
T. Man Pharmaceutical Public Company Limited, or TMAN, has announced it is building a New S-Curve in the Health & Wellness business group through Longevity innovation via the Heaven Herb factory, one of the group's most fully integrated production bases. Chief Executive Officer Praphon Thanachotiphan revealed that the five-year business plan will deliver approximately 15 Science-backed Longevity Solutions products (SKUs), covering metabolic and cellular systems, gut health and inflammation, brain and sleep, as well as skin health. Over the next 3-5 years, the company aims to generate 5-10% of its portfolio revenue from this group, making it a new Growth Engine for the organisation. The company estimates Thailand's Healthcare market value in 2026 at approximately 37.65 billion US dollars, and expects it to rise to approximately 61.38 billion US dollars in 2033, growing at an average of 8.49% per year. Chief Operating Officer Tras Absuwan said the Heaven Herb factory operates on a fully integrated basis, from extracting active substances from herbs to developing and processing them into herbal products, dietary supplements and cosmetics under GMP PIC/S, ISO 22716 and ISO 22000 standards, with a plan to fully transform into a Smart Factory and to operate under an ESG framework. It has received Level 2 Green Industry certification and a Level 3 White Factory award.
Longevity & Life Extension › Metabolic Aging & Geroprotectors Demand
TMAN.BK · Technology · Positive TMAN opens the fully integrated Heaven Herb factory and launches ~15 Science-backed Longevity SKUs, a new product/R&D-driven growth engine targeting 5-10% of revenue.
HL expands iCare branch at Phutthamonthon Sai 4, pushes into Pet Health market in second half of 2026
HL is pressing ahead with full force to expand its customer base in the second half of 2026 by opening a new iCare branch at Phutthamonthon Sai 4, while accelerating the development of innovative products under the Prime brand, a line of health-care supplements including Prime Immuliv, Prime G3 and an absorption-enhancing product, as well as skin-care products and herbal products under the Q brand that have won international awards. The company is also moving into the Pet Health market in line with the pet humanization trend by sourcing and distributing supplements, vitamins and medicines for pets. Meanwhile, PTG has received the Human Rights Awards 2026 at the outstanding level in the large business organisation category for the second consecutive year. TMAN, for its part, has opened the Heaven Herb factory in Pathum Thani province, showcasing the potential of a production base driven by modern technology, with a target of creating 15 new products within five years to meet global demand and the growing longevity trend, while continuing to transform the factory with an investment budget of 50 million baht per year to help drive Thailand toward becoming a Global Wellness Hub.
HL.BK · Demand · Positive HL is expanding its iCare branch network and launching new Prime and Q products plus entering the Pet Health market to grow its customer base.
TMAN.BK · Demand · Positive TMAN opened the Heaven Herb factory targeting 15 new products within five years to meet global demand and the longevity trend.
PTG.BK · Regulation · Positive PTG received the Human Rights Awards 2026 at outstanding level for the second consecutive year.
Oracle and Buck Institute Partner on Federal Aging Research Initiative
Oracle and the Buck Institute for Research on Aging are collaborating to advance research into age-related disease and support discoveries that can extend the healthy years of life. Buck will leverage Oracle Life Sciences Data Intelligence, which encompasses 122 million+ de-identified longitudinal Oracle Health Real-World Data records and advanced analytics, to research biomarkers aimed at enabling early detection and targeted intervention for aging-related complications. The research will also be used to pursue qualification for the first FDA-grade "Intrinsic Capacity Score," a vitality score for healthy aging. The Buck Institute serves as one of the analytics and bioinformatics engines for the Stanford University-led Transforming Health: Reclaiming Intrinsic Vitality for Everyone (THRIVE) consortium, which is a component of the PROactive Solutions for Prolonging Resilience (PROSPR) program from the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services. Using Oracle Life Sciences Data Intelligence, researchers at Buck Institute aim to construct patient cohorts and apply advanced analytics to decades of longitudinal health records to identify subtle clinical changes that may indicate frailty or chronic disease years before onset, and plan to build a statistically validated model capable of predicting which patients are at greatest risk and when.
ORCL · Demand · Positive Oracle's Life Sciences Data Intelligence platform was selected by the Buck Institute to power its aging research, a concrete product adoption/deal.
AIA Partners with VitalLife, Bumrungrad Hospital Network, to Launch Longevity Service in January 2027
AIA Thailand has announced a strategic partnership with VitalLife Wellness Center, part of the Bumrungrad International Hospital network, to develop healthcare and longevity services for high-net-worth customers, with services set to begin in January 2027. AIA's high-net-worth customers will access these services through the AIA Prestige Club program, which had more than 100,000 members as of June 2026. The services cover in-depth health assessments, hormone balance and nutritional analysis, genetic factor evaluation, and consultations to design personalized healthcare approaches. For cases requiring more complex diagnosis or treatment, customers can be connected to Bumrungrad Hospital's network of specialist physicians. Ekachat Thitimun, Chief Health Insurance Business Officer of AIA Thailand, said the partnership elevates the health experience to be more personalized. Meanwhile, Assistant Professor Dr. Polkrit Teekireekul, Chief Executive Officer of VitalLife Wellness Center and Esperance, said the partnership will help elevate Thailand into a Wellness hub. VitalLife has operated in longevity medicine and preventive care for more than 25 years and currently provides services in both Bangkok and Phuket.
Aging Population › Retirement Income & Annuities Demand
AIA Thailand · Demand · Positive AIA Thailand adds personalized longevity and healthcare services for its 100,000+ Prestige Club high-net-worth members through the VitalLife/Bumrungrad partnership.
BH.BK · Demand · Positive Bumrungrad's VitalLife network gains a partnership channeling AIA Prestige Club high-net-worth customers into its longevity and specialist services.
Apple unveils Apple Watch Series 12 and Ultra 4 with new health features
Apple has announced its most advanced health and fitness experience yet, introducing the Apple Watch Series 12 and Apple Watch Ultra 4 with a new Health Sensing System that delivers the most accurate heart rate sensing in a wearable, along with a redesigned Health app powered by Apple Intelligence. The new watches measure heart rate every five seconds and HRV as often as every five minutes, 24 times more frequently, and introduce a readiness score from 0 to 10 with recommendations like Recover or Go For It. The redesigned Health app, coming later this year with iOS 27, adds an Insights tab and a Longevity tab featuring Health Age, which compares users' metrics to their chronological age. Users can also schedule and purchase lab tests covering over 50 biomarkers for $119 at approximately 2,000 Quest Diagnostics locations in the U.S., and new movement assessments use the iPhone camera and Apple Watch for at-home evaluations. The watches also support perimenopause and menopause tracking, and watchOS 27 will be available starting September 14 for Apple Watch Series 9 or later, Apple Watch SE 3, and Apple Watch Ultra 2 or later.
AWC Partners with VitalLife to Open AYA Wellness Club at Empire
Asset World Corp Public Company Limited (AWC) has announced a partnership with VitalLife Scientific Wellness Center, under Bumrungrad Hospital, to open "AYA Wellness Club" at Empire, Thailand's first comprehensive health and lifestyle destination in the heart of Bangkok. The club will operate 24 hours a day, offering preventive health programs, longevity, spa, dining, hydrotherapy, heat therapy, and fitness, with VitalLife serving as advisor on preventive healthcare and Longevity Medicine. Located in Empire, which spans over 48,000 square meters and is certified LEED Gold, WELL Core Platinum, and others, the first phase is set to open in 2026, with full operations in 2027.
AWC.BK · Demand · Positive AWC partners with VitalLife to open AYA Wellness Club at its Empire destination, adding a new tenant/offering to its lifestyle project.
BH.BK · Demand · Positive Bumrungrad's VitalLife unit will serve as advisor on preventive healthcare and longevity medicine for the new AYA Wellness Club.
Genflow Biosciences announced that its SLAB gene therapy trial in ageing dogs has met its primary endpoint, and it is now in talks with major animal health companies about a licensing deal. EnergyPathways has appointed Jacobs as engineering and regulatory partner for its MESH energy storage project in the Irish Sea, moving toward a key Ofgem funding submission. Itaconix is targeting a doubling of revenue to $30 million in the medium term, after half-year revenue jumped 72% on strong detergent demand. Gaming Realms says it is well placed to keep growing despite a UK tax hike hitting margins, with core content licensing revenue up 12% in the first half. Total Graphite reports that fresh drilling in Madagascar has strengthened the case for restarting mining at Vatomina, with one hole returning 19 metres at 3.3% graphite. 80 Mile has agreed indicative terms for a £61.5 million all-share takeover by Nasdaq-listed Greenland Energy, representing a near-47% premium to its share price.
80M.LSE · Capital · Positive Agreed to a £61.5m all-share takeover by Greenland Energy at a near-47% premium
GENF.LSE · Technology · Positive SLAB gene therapy trial in ageing dogs met its primary endpoint, prompting licensing talks with animal health companies
Thai Union Ingredient Launches Longevity Portfolio from Tuna
Thai Union Ingredient (TUI) has launched its Longevity portfolio at Vitafoods Asia 2026, presenting innovative ingredient solutions derived from tuna. The portfolio includes DHA fish oil, collagen, and bio-calcium, all backed by a 100% traceability system across the entire supply chain. These three ingredients are developed from by-products of tuna processing, namely fish heads, skin, and bones, at facilities in Germany, Samut Sakhon, and Songkhla. The company aims to generate at least $30 million in revenue from ThalaCol™ within five years and to increase premium-grade omega-3 oil sales with a compound annual growth rate of over 50% by 2030.
Longevity & Life Extension › NAD+ & Cellular Energetics Supply
Thai Union Ingredient PCL · Demand · Positive Targets at least $30M revenue from ThalaCol within five years and over 50% CAGR in premium-grade omega-3 oil sales by 2030.
Thai Union Ingredient PCL · Technology · Positive Launches Longevity portfolio of tuna-derived DHA fish oil, collagen, and bio-calcium ingredients at Vitafoods Asia 2026.
APCO Q2/2026 Revenue 44.25 Million Baht, Expands Longevity Market with New Mylife100A Formula
APCO reported its Q2/2026 financial results with total revenue of 44.25 million baht and net profit of 11.06 million baht. The company continues to capitalize on the longevity trend by launching the new Mylife100A formula, which features anti-aging and holistic health restoration benefits. The information was provided by Professor Dr. Pichet Viriyachitra, Chief Executive Officer. The company is also expanding its consumer base through BIM Advisor. The details were disclosed at the Opportunity Day event organized by the Stock Exchange of Thailand, and the recording can be viewed at www.set.or.th/streaming/vdos-oppday.
SNPS Signals Positive Second Half with Net Profit of 44.25 Million Baht
Specialty Natural Products Public Company Limited, or SNPS, reported its operating results for the first half of 2026, with total revenue of 259.19 million baht, of which revenue from sales and services was 250.14 million baht, accounting for 96.51% of total revenue, and a net profit of 44.25 million baht, maintaining a net profit margin of 17.07%, reflecting efficient management. The company views the trends of consumers in the Longevity and Preventive Health groups as opportunities to expand its business, while elevating Thai herbs from commodities to premium products and expanding markets both domestically and internationally. This signals a positive second half, as it strives to be a leader in the production and extraction of Thai herbs to global standards.
Longevity & Life Extension › NAD+ & Cellular Energetics ▲Demand
SNPS.BK · Capital · Positive SNPS reported H1 2026 revenue of 259.19M baht and net profit of 44.25M baht with a 17.07% margin, signaling a positive second half.
APCO Upgrades Mylife100A with New Formula, Targets Longevity Market
APCO has launched a new formula of Mylife100A to cater to the Longevity trend, focusing on cellular health restoration and reducing the risk of dementia. The company plans to publish its research in an international academic journal by September. It will expand its customer base through BIM Advisor and is preparing to export to South Africa via partner INFINITUM GLOBAL HEALTH, with an initial order of 1,500,000 bottles in the first year. For the second quarter of 2026, the company reported total revenue of 44.25 million baht and net profit of 11.06 million baht. In the first half of the year, total revenue was 93.81 million baht and net profit was 28.95 million baht.
TPOC points to global health market of 6.7 trillion dollars boosting Thai herbs
The Trade Policy and Strategy Office revealed that health care and anti-aging trends will push global consumer spending on medical goods and services to as high as 6.7 trillion US dollars by 2040, more than doubling compared with the past 15 years. In 2025, Thailand's retail value in the herbal product group was 1.3575 billion US dollars, ranking 11th in the world, and is expected to reach 1.8364 billion US dollars by 2030. Consumers are willing to pay at least 20 percent more if products have scientific test results to support them. The Trade Policy and Strategy Office proposed four urgent strategies: upgrading agricultural extracts to the medical level, penetrating everyday products and personalized nutrition, integrating technology for personalized health care, and linking the service ecosystem with health tourism under the Agri-Wellness Synergy concept to transform Thailand's agricultural sector into a health economy.
Insilico Medicine Launches Virtual Aging Cell Platform
Insilico Medicine has launched its Virtual Aging Cell webpage and previewed a multi-agent driven platform that uses biological age as a core condition for simulating cellular dynamics. The platform deploys agent swarms across six biological scales—molecular, intracellular, intercellular, tissue, organ, and organism—to model differentiation, reprogramming, and aging, aiming to support target identification and drug discovery. The launch follows a decade of work including the PreciousGPT model series, with the company noting it has nominated 33 preclinical candidates since 2021, 13 of which have received IND approvals or clearances. Insilico will present further details at the ARDD 2026 conference in Boston.
Abacus Global Management Q2 2026 Earnings Beat Guidance
Abacus Global Management reported second quarter 2026 results that exceeded its own guidance, with total revenue of $73.0 million, up 30% year over year, and adjusted net income of $27.1 million, above the high end of its $24 million to $26 million forecast. Adjusted EPS was $0.28, up 22% from $0.23 a year earlier, and adjusted EBITDA rose 27% to $39.9 million. The company's Life Solutions segment drove growth with revenue of $65.4 million, a 38.3% increase, while longevity fund inflows reached $544.2 million in the first half, surpassing its $500 million target. Management provided third quarter guidance of $26 million to $28 million in adjusted net income and reiterated full-year adjusted net income of $100 million to $106 million. The company also announced the launch of its first registered interval fund, the ABX Longevity Growth and Income Fund, and a $53 million minority investment in Manning & Napier.
GFC accelerates in second half, expanding into foreign markets and new business joint ventures
Genesis Fertility Center Public Company Limited, or GFC, announced its plan for the second half of 2026, aiming to expand its foreign customer base from 15 percent to 25 percent through a network of nine overseas agents and partnerships with eight partner hospitals. The company is also studying new business joint ventures in anti-aging services and ICSI centers to create a new S-curve. For the first six months, revenue was 125.54 million baht, down 30.30 percent, with a net loss of 9.92 million baht, compared with a net profit of 15.40 million baht in the same period last year. However, egg freezing and egg storage services grew 41.64 percent. The board of directors approved an interim dividend of 0.03 baht per share, totaling 6.60 million baht, to be paid by September 8, 2026.
BIZ reports Q2 2026 profit surges 87% to 85 million baht, advances BIZGENES to tap longevity market
Business Alignment Public Company Limited, or BIZ, reported second-quarter 2026 net profit of 85.18 million baht, up 87.75 percent from 45.37 million baht in the same period last year. Total revenue reached 542.57 million baht, a 29.51 percent increase from 418.94 million baht, driven mainly by the delivery of radiation therapy machines and medical equipment according to plan. CEO Sompong Chuenkittiyanont said the company will press ahead with expanding BIZGENES, a personalized DNA analysis platform, to capture the trend of preventive and personalized healthcare, while broadening service channels across hospitals, clinics, and general consumers. The company also plans to bid for new projects and negotiate with partners to support future projects, expressing confidence that full-year 2026 performance will grow as targeted, backed by its order backlog and rising after-sales maintenance revenue.
Life Biosciences appoints Stephen Webster to board of directors
Life Biosciences has appointed Stephen Webster to its board of directors, effective August 1, 2026. Webster is a biotechnology executive who has served as chief financial officer of three public companies and played a key role in multiple financings, commercial launches, and acquisitions. He previously led approximately $1 billion in equity financings at Spark Therapeutics, oversaw its 2015 initial public offering, supported the commercial launch of LUXTURNA, and helped lead the company's $4.3 billion acquisition by Roche. Life Biosciences is a clinical-stage biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, with a lead program in development for optic neuropathies.
MEDEZE Partners with Bangkok Hospital Udon to Offer Comprehensive Health Services
Medeze Group Public Company Limited, or MEDEZE, has signed a memorandum of understanding with Bangkok Hospital Udon to develop innovative medical and holistic healthcare services. The collaboration covers personal stem cell storage, hair root cell storage, immune potential testing, as well as the promotion of anti-aging medicine and precision medicine at Bangkok Hospital Udon in Udon Thani province. MEDEZE is a leader in stem cell banking with internationally recognized standards and is the first in Thailand to achieve cell bank accreditation.
Merz Aesthetics Partners with NSTDA's Nanotec to Research Aesthetic Longevity, Pushing Thailand as a Global Beauty Hub
Merz Aesthetics and the National Nanotechnology Center under NSTDA have signed a research collaboration on Aesthetic Longevity to elevate Thailand's beauty industry into a global hub. The goal is to transition from being a user of foreign innovations to a standard-setter and knowledge creator, supporting Thailand's health economy market valued at 1.4 trillion baht under the Thailand Global Health Hub 2025 to 2034 strategy. This partnership will leverage Nanotec's cellular-level research platforms, such as telomere analysis and epigenetic clock, together with Merz's technologies to generate scientific evidence that meets the needs of modern consumers who seek in-depth information before deciding on beauty services. Both parties view evidence-driven approaches as the key to market competition, enabling physicians to plan personalized treatments with greater precision and safety.
Anti-Aging Supplements Market Projected to Reach USD 10.65 Billion by 2035
The global anti-aging supplements market is projected to reach USD 10.65 billion by 2035, growing at a compound annual growth rate of 7.88 percent from 2026 to 2035, according to a new report by SNS Insider. The market was valued at USD 5.00 billion in 2025. North America led with approximately 37 percent of global revenue in 2025, while the Asia Pacific region is expected to record the fastest growth at an 8.39 percent CAGR. The collagen segment held the largest ingredient share at about 69.22 percent in 2025, and the capsules and tablets formulation segment dominated due to convenience and precise dosage.
Animal Longevity Summit to hold first global scientific forum on healthy aging in animals
The Animal Longevity Summit has announced its inaugural two-day scientific conference, taking place October 1–2, 2026, in Toronto. The event will bring together leading experts in geroscience, veterinary medicine, biotechnology, and aging research to explore how the biology of aging can be measured, slowed, and translated into longer, healthier lives, beginning with animals. The summit arrives as landmark initiatives such as the Dog Aging Project and a growing number of veterinary clinical trials generate the first large-scale datasets on interventions to improve healthspan and longevity in companion animals. The conference program will feature eight scientific tracks covering canine longevity, comparative biology of aging, biomarkers, longevity interventions, veterinary geroscience, cross-species translation to human health, and emerging research from early-career scientists. The inaugural speaker lineup includes Dr. Matt Kaeberlein of the Dog Aging Project, Dr. Vera Gorbunova of the University of Rochester, Dr. Aubrey de Grey of the LEV Foundation, Dr. Varun Dwaraka of TruDiagnostic, Liz Parrish of BioViva, and Dr. Raghav Sehgal of Yale, with additional speakers to be announced. Industry participation is also expected, with Genflow Biosciences confirming it will present new findings from its SLAB study investigating gene therapy in aged beagles.
Hofseth BioCare study shows ProGo salmon peptides improved GLP-1 markers and lean muscle mass
Hofseth BioCare ASA announced the publication of a peer-reviewed clinical study in Biomedicines showing that its salmon protein hydrolysate ProGo improved multiple biological markers linked to healthy ageing and metabolic health in overweight adults, while a protein-matched whey comparator did not. The randomised, double-blind, active-controlled pilot study enrolled 14 overweight adults who received either 12 grams per day of ProGo or an iso-nitrogenous whey protein isolate for 56 days. ProGo produced statistically significant improvements versus whey in haemoglobin, red blood cell count, mean corpuscular haemoglobin, ferritin, and a composite self-assessed hair, nail and skin score, with a 39.1 percent improvement in the composite score. Exploratory analyses favoured ProGo across body composition, inflammation and glucose metabolism, including a 13.3 percent increase in lean body mass, reductions in waist circumference, BMI and percent body fat, and improvements in inflammatory markers and HbA1c. The company noted the findings are preliminary and that larger, longer and placebo-controlled studies are warranted.
Denmark
United States
